{
  "image_filename": "figure_p10_det_9_000.png",
  "image_path": "Grohskopf_et_al.__2023_/extracted/figures/figure_p10_det_9_000.png",
  "image_type": "Figure",
  "page_number": 10,
  "block_id": "det_9_000",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Flowchart decision tree for pediatric influenza vaccination: asks if a child received two or more doses of trivalent or quadrivalent influenza vaccine before July 1, 2022; if yes, recommends one dose of 2022\u201323 influenza vaccine; if no or unknown, recommends two doses of 2022\u201323 influenza vaccine administered four weeks apart. does not support the claim: the figure presents a dosing algorithm for children's influenza vaccination and makes no reference to Flublok, Fluarix, or any pivotal trial comparison.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Flowchart decision tree for pediatric influenza vaccination: asks if a child received two or more doses of trivalent or quadrivalent influenza vaccine before July 1, 2022; if yes, recommends one dose of 2022\u201323 influenza vaccine; if no or unknown, recommends two doses of 2022\u201323 influenza vaccine administered four weeks apart.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the figure presents a dosing algorithm for children's influenza vaccination and makes no reference to Flublok, Fluarix, or any pivotal trial comparison.",
    "confidence_notes": null
  }
}